Funding for this research was provided by:
Cancer Research UK (C8218/A21453)
Worldwide Cancer Research (16-0390 2016)
Received: 23 October 2019
Accepted: 18 February 2020
First Online: 10 March 2020
: The authors have no competing interests except Y.W., J.J.C., R.S., P.Z. and T.J.S. who are all employees of ChemoCentryx and developed and provided the CCr1i/CCR2i double inhibitor for the study.